Physician profile
J Ryan Jackson
NPI 1346633161
$5,790.52
in general payments reported to CMS, 2019-2025
24 companies · $761 in 2025
The $761 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $333 · 2021: $778 · 2022: $697 · 2023: $1,373 · 2024: $1,258 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,093 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,092.64 |
| Education | $298.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,373.76 | 2019-2025 | Dupixent, Libtayo |
| Abbvie INC. | $906.19 | 2019-2024 | |
| Janssen Biotech, INC. | $799.85 | 2019-2025 | Tremfya, Remicade, Stelara |
| Leo Pharma INC. | $394.79 | 2019-2025 | Adbry |
| Genzyme Corporation | $297.63 | 2021-2025 | |
| Pfizer INC. | $255.89 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $236.26 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $216.50 | 2019-2024 | Jublia |
| Sun Pharmaceutical Industries INC. | $188.96 | 2021-2025 | Winlevi, Absorica Ld |
| Lilly USA, LLC | $183.12 | 2021-2024 | Taltz, Olumiant |
| Amgen INC. | $179.83 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $175.07 | 2019-2024 | Bimzelx |
| Galderma Laboratories, L.P. | $113.85 | 2021-2025 | Nemluvio, Epsolay, Twyneo |
| Epi Health, LLC | $79.40 | 2019-2021 | |
| Biowound Solutions, INC. | $70.61 | 2025 | Bio-Connekt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $57.64 | 2021-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $51.75 | 2021 | |
| Celgene Corporation | $42.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.28 | 2023-2025 | Sotyktu |
| Dermira, INC. | $32.24 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $29.98 | 2023 | |
| Mayne Pharma Commercial LLC | $25.09 | 2019-2023 | |
| Kyowa Kirin, INC. | $23.98 | 2021 | |
| Biofrontera INC. | $18.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Ryan Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.